Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18782879 | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR | July 2024 | December 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18670566 | METHOD OF TREATMENT AND SELECTION OF PATIENTS BENEFITING FROM AGOMELATINE BASED ON EEG MEASUREMENTS | May 2024 | January 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 18626740 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | April 2024 | March 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18602126 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | March 2024 | March 2025 | Allow | 12 | 0 | 0 | No | No |
| 18600365 | DNA POLYMERASE THETA INHIBITOR FOR TREATMENT OF CANCER | March 2024 | June 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18586920 | Pleiotropic Pathway Modifier Compounds and Method of Treating Diseases | February 2024 | September 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18418168 | PYRAZOLO[1,5-C]PYRIDO[3,4-E]PYRIMIDINES AS CK2 INHIBITORS | January 2024 | September 2024 | Allow | 8 | 1 | 0 | No | No |
| 18345461 | USE OF BROMODOMAIN-CONTAINING PROTEIN 9 INHIBITORS TO TREAT AND/OR PREVENT UTERINE LEIOMYOSARCOMA | June 2023 | March 2025 | Allow | 21 | 3 | 0 | Yes | No |
| 18209674 | SOLID FORMS OF JAK INHIBITOR AND PROCESS OF PREPARING THE SAME | June 2023 | October 2024 | Abandon | 17 | 1 | 1 | No | No |
| 18329958 | COMPOSITIONS AND METHODS FOR WILLIAMS SYNDROME (WS) THERAPY | June 2023 | June 2025 | Abandon | 24 | 2 | 0 | No | No |
| 18198191 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | May 2023 | April 2025 | Abandon | 23 | 2 | 1 | No | No |
| 18140576 | POLYMORPHS OF [2-(1H-INDOL-3-YL)-1H-IMIDAZOL-4-YL](3,4,5-TRIMETHOXYPHENYL)METHANONE AND ITS SALTS | April 2023 | December 2024 | Allow | 20 | 1 | 1 | No | No |
| 18131314 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | April 2023 | October 2024 | Allow | 19 | 2 | 1 | No | No |
| 18125940 | INTRANASAL OLANZAPINE FORMULATIONS AND METHODS OF THEIR USE | March 2023 | August 2024 | Allow | 17 | 2 | 1 | No | No |
| 18025817 | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR | March 2023 | January 2025 | Allow | 22 | 0 | 0 | Yes | No |
| 17822344 | EIF4E INHIBITORS AND USES THEREOF | August 2022 | August 2024 | Allow | 24 | 2 | 1 | No | No |
| 17870476 | REAGENTS, COMPOSITIONS AND METHODS FOR IMPROVING VIABILITY AND FUNCTION OF CELLS, TISSUES AND ORGANS | July 2022 | May 2025 | Allow | 33 | 3 | 2 | Yes | No |
| 17791755 | MEK INHIBITORS AND THERAPEUTIC USES THEREOF | July 2022 | April 2025 | Allow | 33 | 0 | 0 | No | No |
| 17854801 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | June 2022 | July 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17749958 | CONJUGATE MONOMETHYL AURISTATIN E TO OBTAIN A COMPOSITION FOR TREATMENT OF PROSTATE CANCER | May 2022 | June 2025 | Allow | 36 | 0 | 0 | No | No |
| 17655020 | NOVEL PHARMACEUTICAL COMPOSITIONS | March 2022 | February 2025 | Abandon | 35 | 2 | 1 | No | No |
| 17538919 | TIME TO RESOLUTION OF AXITINIB-RELATED ADVERSE EVENTS | November 2021 | June 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17602426 | ANTIBACTERIAL COMPOUNDS | October 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17437264 | PESTICIDALLY ACTIVE AZOLE-AMIDE COMPOUNDS | September 2021 | March 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17435803 | Compounds for Treating Neurodegenerative Diseases and Cancers | September 2021 | March 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17435939 | SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION | September 2021 | February 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17435031 | BENZOTHIOPHENE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | August 2021 | January 2025 | Allow | 40 | 1 | 0 | No | No |
| 17412102 | DUAL MAGL AND FAAH INHIBITORS | August 2021 | February 2025 | Allow | 41 | 2 | 0 | Yes | No |
| 17428734 | TUFT CELL SPECIFICATION IN INFLAMMATORY ILEITIS | August 2021 | November 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17305773 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | July 2021 | October 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17422642 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | July 2021 | March 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17422252 | NLRP3 MODULATORS | July 2021 | July 2024 | Allow | 36 | 0 | 1 | Yes | No |
| 17422434 | TRANSDERMAL PENETRANT FORMULATIONS CONTAINING CANNABIDIOL | July 2021 | November 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17421533 | PALATABLE FORMULATIONS | July 2021 | August 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17421567 | METALLOENZYME INHIBITOR COMPOUNDS | July 2021 | March 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 16499771 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | July 2021 | May 2025 | Allow | 60 | 2 | 1 | Yes | No |
| 17366923 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | July 2021 | February 2025 | Allow | 43 | 1 | 1 | No | No |
| 17419956 | COMBINATION THERAPY OF PHOSPHATE BINDERS AND VITAMIN K | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17415492 | AMINOPYRIMIDINE COMPOUND USED FOR INHIBITING ACTIVITY OF PROTEIN KINASE | June 2021 | January 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17309646 | SALT OF SYK INHIBITOR AND CRYSTALLINE FORM THEREOF | June 2021 | October 2024 | Allow | 40 | 1 | 0 | No | No |
| 17335202 | Use of fumaric acid esters and pharmaceutically acceptable salts thereof in preparing pharmaceuticals for treating ferroptosis-related diseases | June 2021 | December 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17293817 | INHIBITOR OF BRUTON TYROSINE KINASE | May 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17292891 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | May 2021 | April 2025 | Allow | 48 | 1 | 1 | No | No |
| 17292036 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | May 2021 | March 2025 | Allow | 46 | 1 | 1 | No | No |
| 17291416 | FEED ADDITIVE FOR DAIRY CATTLE COMPRISING N-ACETYL-L-TRYPTOPHAN AS ACTIVE INGREDIENT | May 2021 | April 2025 | Abandon | 47 | 2 | 0 | Yes | No |
| 17244039 | Use of Trimetazidine in Preparation of Drugs for Preventing and Treating Liver Diseases | April 2021 | October 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17289736 | PROGNOSIS AND TREATMENT OF METASTATIC CANCER | April 2021 | October 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17289470 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | April 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17289062 | NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | April 2021 | April 2024 | Allow | 35 | 0 | 1 | Yes | No |
| 17239086 | CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE | April 2021 | March 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17285840 | PYRIDYLPHENYLAMINOQUINOLINES AND ANALOGUES | April 2021 | October 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17230009 | PROCESS FOR PREPARING A COMPOUND OF FORMULA (XIII) | April 2021 | September 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17285214 | COMPOSITION AND METHOD OF STRENGTHENING SKIN BARRIER | April 2021 | March 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17224557 | HIV INHIBITOR COMPOUNDS | April 2021 | April 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17250938 | NOVEL OXADIAZOLES | March 2021 | June 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17281748 | METHODS FOR THE TREATMENT OF SCLERODERMA | March 2021 | September 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17277954 | SMALL MOLECULE MENIN INHIBITORS | March 2021 | August 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17276821 | TREATMENT FOR OBESITY | March 2021 | April 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17271202 | BTK INHIBITORS, PHARMACEUTICALLY ACCEPTABLE SALTS, POLYMORPHS AND APPLICATION THEREOF | February 2021 | August 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17268512 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | February 2021 | December 2023 | Allow | 34 | 0 | 0 | Yes | No |
| 16646081 | Process for preparing crystalline Tipiracil Hydrochloride | March 2020 | December 2024 | Abandon | 58 | 1 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner SCHMIDT, IZABELA MARIA works in Art Unit 1621 and has examined 54 patent applications in our dataset. With an allowance rate of 51.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner SCHMIDT, IZABELA MARIA's allowance rate of 51.9% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SCHMIDT, IZABELA MARIA receive 1.06 office actions before reaching final disposition. This places the examiner in the 14% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by SCHMIDT, IZABELA MARIA is 41 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +63.9% benefit to allowance rate for applications examined by SCHMIDT, IZABELA MARIA. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 41.7% of cases where such amendments are filed. This entry rate is in the 57% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 96% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 21.4% of allowed cases (in the 93% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.